U.S. markets open in 7 hours 19 minutes

VBI Vaccines Inc. (VBIV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.3200-0.3000 (-8.29%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close3.6200
Bid0.0000 x 2900
Ask0.0000 x 4000
Day's Range3.3100 - 3.5800
52 Week Range0.6900 - 6.9300
Avg. Volume7,606,810
Market Cap803.616M
Beta (5Y Monthly)1.99
PE Ratio (TTM)N/A
EPS (TTM)-0.2060
Earnings DateMar 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • VBI Vaccines Stock Could Blast Higher by 170%, Says Analyst

    VBI Vaccines Stock Could Blast Higher by 170%, Says Analyst

    Several small-cap biotech firms have used the coronavirus as a springboard, and since the pandemic’s onset many have become almost household names. Despite making meaningful market strides over the past year, VBI Vaccines (VBIV) is not one that immediately springs to mind. However, Raymond James analyst Steven Seedhouse claims the company could yet make an indelible mark in the fight against Covid-19. VBI’s monovalent Covid-19 vaccine candidate is expected to enter Phase 1/2 trial this month and following pre-clinical data which showed the vaccine compared well against Novavax’ Covid-19 vaccine, Seedhouse believes it may end up being “the most efficacious of any.” “Given the dose planned for human use is evidently >10-fold the dose tested in mice, we expect the strong preclinical data to translate to humans,” the analyst said. “Moreover, VBI has replicated the strong mouse findings in 2 other animal models including hamsters. We aren't sure the Street really appreciates yet 1) the tail on the COVID vaccine market and 2) just how strong VBI's vaccine may end up being.” Furthermore, on the Covid-19 front, sometime in 2021, VBI’s pan-coronavirus vaccine (Cov-2, SARS, MERS) will also the enter clinic. However apart from Covid-19, there are other upcoming “value drivers.” A November 30 PDUFA date has been set for VBI’s prophylactic HBV vaccine. Seedhouse says, an anticipated mid-year manufacturing plant inspection could be a “key hurdle,” although the plant met the required standards before - Sci-B-Vac was given the commercial go-ahead in Israel. While FDA requirements are more stringent, the plant has since been given a makeover to meet the FDA’s standards and his since passed a mock audit. Additional tailwinds could be provided from the final data of the Phase 1 glioblastoma (GBM) vaccine trial, which is anticipated in 1H21 and the kickoff this quarter of a Phase 2b/3 trial in Southeast Asia/China with partner Brii Bio, studying VBI's HBV vaccine VBI-2601 together with RNAi therapeutic BRII835. Based on all of the above, Seedhouse rates VBIV a Strong Buy along with a $9 price target. The figure implies a whopping ~170% upside potential from current levels. (To watch Seedhouse’ track record, click here) Only one other analyst has recently posted a VBIV review, but it is also wholly enthusiastic. The extra Buy results in a Moderate Buy consensus rating. Backed by an $8 average price target, the stock is expected to add 138% of muscle over the next 12 months. (See VBIV stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Lags Revenue Estimates

    VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Lags Revenue Estimates

    VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0.00% and -62.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

  • VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2020, Provides Corporate Update and Outlook for 2021
    Business Wire

    VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2020, Provides Corporate Update and Outlook for 2021

    VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the fourth quarter and twelve months ended December 31, 2020. The Company also provided a corporate update and its outlook for 2021.